Follitropin beta biosimilar - Reliance Life Sciences

Drug Profile

Follitropin beta biosimilar - Reliance Life Sciences

Alternative Names: FostiRel

Latest Information Update: 01 Oct 2013

Price : $50

At a glance

  • Originator Reliance Life Sciences
  • Class Follicle stimulating hormones; Infertility therapies; Peptide fragments; Pituitary gonadotropins
  • Mechanism of Action Gonadal steroid hormone stimulants; Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Female infertility; Sex hormone disorders

Most Recent Events

  • 26 Oct 2012 Launched for Sex hormone disorders (spermatogenesis in males) in India (SC) before October 2012
  • 26 Oct 2012 Launched for Female infertility in India (SC) before October 2012
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top